$425 Million is the total value of Clarus Ventures, LLC's 10 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 200.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
NSTG | Buy | Nanostring Technologies Inc. | $71,962,000 | +32.9% | 4,036,025 | +1.9% | 16.91% | -12.2% |
GRTS | New | Gritstone Oncology Inc | $36,560,000 | – | 2,567,445 | +100.0% | 8.59% | – |
ETTX | New | Entasis Therapeutics Holdings Inc | $17,663,000 | – | 1,623,405 | +100.0% | 4.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Nanostring Technologies Inc. | 20 | Q3 2018 | 60.2% |
Sientra Inc. | 16 | Q3 2018 | 38.2% |
Oxford Immunotex Global PLC | 14 | Q1 2017 | 17.4% |
Catabasis Pharmaceuticals Inc. | 14 | Q3 2018 | 15.3% |
VBI Vaccines Inc. | 10 | Q3 2018 | 11.4% |
TetraLogic Pharmaceuticals Corporation | 9 | Q4 2015 | 12.5% |
ESSA Pharma Inc. | 9 | Q1 2018 | 6.5% |
Aerie Pharmaceuticals Inc. | 7 | Q4 2015 | 30.5% |
VBI Vaccines Inc. | 7 | Q1 2016 | 9.1% |
Ophthotech Corp | 6 | Q1 2015 | 31.5% |
View Clarus Ventures, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-NT | 2024-02-14 |
13F-NT | 2023-11-14 |
13F-NT | 2023-08-14 |
13F-NT | 2023-05-15 |
13F-NT | 2023-02-14 |
13F-NT | 2022-11-14 |
13F-NT | 2022-08-15 |
13F-NT | 2022-05-16 |
13F-NT | 2022-02-14 |
13F-NT | 2021-11-15 |
View Clarus Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.